Meet
Kylie Stengel

Kylie Stengel supports clients spanning a range of healthcare sectors and stakeholders in assessing the impacts of the evolving policy landscape on their business and advocacy priorities.

She focuses on regulatory and legislative developments, with specific expertise in Medicare Part D payment and policy, drug pricing reforms, and health insurance markets.

Kylie has previous experience in the MedStar Georgetown Transplant Institute, where she helped lead a process improvement plan to enhance operating efficiency and patient experience. Additionally, she has experience with the Marwood Group, where she supported the life sciences team to synthesize research and deliver industry analysis, including surveying the regulatory and legislative outlook for pharmaceutical and biotechnology companies.

Kylie has a BS in healthcare management policy from Georgetown University’s School of Nursing and Health Studies.

Authored Content


As policymakers increasingly consider policy options to reform Medicare Part D and reduce program expenditures, an Avalere analysis examines spending across classes with various availability of brand and generic drugs.